Evaluation of Tibial Nerve Selective Neurotomy Compared to Botulinum Toxin Injections for Spastic Foot Treatment in Post-stroke Patients According to a Goal-centered Approach
NCT05874154 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2025-07-14
Summary
In France, more than 110.000 patients are hospitalized for stroke per year. It is the leading cause of sudden disabilities in adults. Incidence of spastic foot is evaluated at 1 year post stroke from 18% to 56% of hemiplegic patients. Spasticity, defined as an increase in the velocity-dependent response to muscle stretch measured at rest, is part of the upper motor neuron syndrome and is characterized by an increase in tonic stretch reflex. It has been proposed that upper motor neuro syndrome may induce not only spasticity but also other types of muscles overactivity such as spastic dystonia, co-contraction and clonus. In hemiplegic patients, lower limb spasticity within the posterior part of the leg frequently results in equino-varus foot and toes claw. These abnormal postures in hemiplegics may affect activities of daily living such as shoes fitting, balance, ambulation-walking, comfort (pain) and may become irreducible (tendon shortening) if not treated.
The purpose of this study is to compare the interest of each treatment (BoNT-A versus STN) in order to specify both techniques indications and up-date current guidelines of lower-limb spasticity for hemiplegic patients.
This study aims to confirm a greater reduction of calf muscles spasticity after STN as compared to BoNT-A, as observed in the only published monocentric randomized controlled trial. Our study originality is to perform a multi-center RCT with a pre-established sample size. This study will also quantify progress towards personal goals using the goal attainment scaling (GAS) and will assess other components related to the consequences of carve muscle spasticity on balance, ambulation, self-care and quality of life.
Conditions
- Post Stroke Seizure
- Spastic Foot
Interventions
- PROCEDURE
-
Tibial nerve selective neurotomy
Patients in the STN group will undergo a pre-anaesthetic visit before surgery to validate the possibility of general anesthesia. The surgery will be performed at maximum 3 months after inclusion. The muscles that have been defined pre-randomization will be targeted by the surgery. The duration of the surgery is about 1 hour and 30 minutes.
- DRUG
-
Botulinum toxin injection
Patients in the BoNT group will be treated with BoNT A under electromyography, electrical stimulation and/or ultrasound guidance (V0). In the absence of scientific evidence between the efficacy of onabotulinumtoxin A and abobotulinumtoxin A, physician will be free to choose between these two BoNT formulation which are both authorized for the treatment of lower limb spasticity. The physician will determine the muscles targeted by the BoNT (gastrocnemius and soleus for equinus, posterior tibialis for varus, and long flexor digitorum and flexor hallucis for claw toes), the appropriate dose and dilution based on his experience, following a semi-guided table of equivalence for respective doses of onabotulinumtoxin A and abobotulinumtoxin A. A delay superior to 3 months will be respected after the last injection and the muscles that have been defined pre-randomization will be targeted by injections.
Sponsors & Collaborators
-
Hospices Civils de Lyon
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-01-02
- Primary Completion
- 2027-03-02
- Completion
- 2027-03-02
Countries
- France
Study Locations
More Related Trials
-
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
NCT03992404 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Botulinum Toxin Efficiency on Spasticity of Rectus Femoris and Semitendinosus Muscles as Functional Agonist and Antagonist Muscles
NCT00133861 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Spastic Cocontractions and Limitation of Active Movements Before and After Treatment During Injection of Botulinum Toxin
NCT03453008 ·Status: UNKNOWN
-
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
NCT01464307 ·Status: COMPLETED ·Phase: PHASE3
-
Adult Subjects Suffering From Lower Limb Spasticity Following Stroke
NCT01444794 ·Status: COMPLETED
-
BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity
NCT01575054 ·Status: COMPLETED ·Phase: PHASE3
-
Central Effects of Botulinum Toxin: Neurophysiological Study in Stroke Patients With Spastic Lower Limb
NCT01829763 ·Status: UNKNOWN ·Phase: PHASE3
-
Effectiveness of Two Techniques in Injection Site Spotting for Botulinum Toxin Injections: Echography or Electro Stimulation.
NCT01935544 ·Status: COMPLETED ·Phase: NA
-
HEMITOX : Effect of Botulinum Toxin Injections on Motor and Functional Ability of Upper Limb in Adults at Earlier Phases of Spastic Hemiplegia After Stroke
NCT00276185 ·Status: UNKNOWN ·Phase: PHASE3
-
Comparison of Two Botox Injection Techniques to Improve Gait
NCT07124806 ·Status: COMPLETED ·Phase: NA
-
Treatment of Spastic Equinovarus Foot After Stroke
NCT00199589 ·Status: COMPLETED ·Phase: NA
-
The Effect of Ultrasound-Guided Botulinum Toxin Injections on Pain, Functionality, Spasticity, and Range of Motion in Patients With Post-Stroke Upper Extremity Spasticity
NCT05887479 ·Status: WITHDRAWN ·Phase: PHASE4
-
Pilot Study on Muscle, Tendon, and Neural Changes Post-Botulinum Toxin Injections in Post-stroke Spastic Equinovarus
NCT06767631 ·Status: RECRUITING ·Phase: NA
-
Early Botulinum Toxin for Muscle Stiffness Reduction in First-Time Stroke Patients: Improving Recovery and Independence
NCT06811142 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
The Effect of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity
NCT05889026 ·Status: COMPLETED ·Phase: NA
-
Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity
NCT02358005 ·Status: UNKNOWN ·Phase: PHASE4
-
Pain During Injection With Botulinum Toxin in Post-stroke Spasticity Treatment
NCT03251521 ·Status: COMPLETED
-
Changes in Echogenicity and Muscle Stiffness in Elastography After Botulinum Toxin Injection a Spastic Muscle
NCT02550509 ·Status: TERMINATED ·Phase: NA
-
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke
NCT01392300 ·Status: COMPLETED ·Phase: PHASE3
-
Dry Needling and Botulinum Toxin in the Management of Poststroke Spasticity
NCT03747900 ·Status: COMPLETED ·Phase: NA
-
Effects of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot
NCT03044080 ·Status: COMPLETED ·Phase: PHASE4
-
Observational Longitudinal Study on the Outbreak and Management of Stroke Related Spasticity
NCT05379413 ·Status: UNKNOWN
-
Comparative Study of the Effects of Dry Needling and Botulinum Toxin Type A as a Treatment for Lower Limb Post-stroke Spasticity
NCT06296082 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Botulinum Toxin Applications in Hemiplegic Patients
NCT07240337 ·Status: RECRUITING
-
Biomechanical and Neurophysiological Evaluation of the Effect of a Motor Block and an Injection of Botulinum Toxin on the Stiffness of the Paretic Sural Triceps Muscle
NCT04717141 ·Status: COMPLETED ·Phase: NA